Fig. 7.

The role of YAP in NGO-promoted angiogenesis in vivo. (a) HE staining and (b) CD31 immunohistochemical staining of the defective region 2 weeks after implantation in the NGO/GelMA groups with or without the YAP inhibitor verteporfin (10 μM). Scale bar, 100 μm. (c) 3D images of angiogenesis in the area of the calvarial defect 2 weeks after surgery. (d) CD31 and Emcn IF double staining revealing newly formed H-type blood vessels in the bone defect region (Scale bar, 50 μm), and the percentages of H-type blood vessels 2 weeks after surgery in rats treated with or without verteporfin were quantified. Data represent the mean ± SD (n = 6). ***p < 0.0001.